Clinical Trial: Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors

This study is no longer recruiting patients.

Sponsors and Collaborators: National Cancer Institute (NCI)
Robert H. Lurie Cancer Center
Information provided by: National Cancer Institute (NCI)


RATIONALE: Perfusion magnetic resonance imaging may be an effective method of measuring the growth of blood vessels in brain tumors. These measurements may help doctors better diagnose and treat brain tumors. PURPOSE: Pilot study to determine the effectiveness of perfusion magnetic resonance imaging in measuring the growth of blood vessels in newly diagnosed brain tumors.

Condition Treatment or Intervention
genetic condition
adult brain tumor
Brain Tumor
stage/type, adult brain tumor
body system/site cancer
central nervous system cancer
adult solid tumor
solid tumor
 Drug: gadopentetate dimeglumine

MedlinePlus related topics:  Brain Cancer;   Cancer;   Cancer Alternative Therapy;   Genetic Disorders;   Neurologic Diseases

Study Type: Interventional
Study Design: Diagnostic

Official Title: Pilot Diagnostic Study of Perfusion Magnetic Resonance Imaging As a Measurement of Angiogenesis in Patients With Newly Diagnosed Surgically Resectable Brain Tumors

Further Study Details: 

Study start: February 2000

OBJECTIVES: I. Correlate the findings of perfusion magnetic resonance imaging with known tissue and serum markers of angiogenesis in patients with newly diagnosed surgically resectable brain tumors.

PROTOCOL OUTLINE: Patients undergo perfusion magnetic resonance imaging (MRI) scanning with contrast in conjunction with preoperative conventional MRI scanning with contrast. Patients receive gadopentetate dimeglumine IV over 5 seconds prior to perfusion MRI. Gadopentetate dimeglumine is administered at a slower rate prior to conventional MRI. Patients undergo blood draw to determine urokinase type plasminogen activator levels. After completion of perfusion and conventional MRI scanning, brain tumor tissue samples are obtained during surgical resection to determine tumor grade and type and urokinase type plasminogen activator and basic fibroblast growth factor levels. If CSF removal is required during surgery, then CSF samples are collected to determine urokinase type plasminogen activator and basic fibroblast growth factor levels.

PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.


Ages Eligible for Study:  18 Years and above



--Disease Characteristics--

  • Newly diagnosed surgically resectable brain tumor

--Prior/Concurrent Therapy--

  • Biologic therapy: Not specified
  • Chemotherapy: No prior chemotherapy
  • Endocrine therapy: Not specified
  • Radiotherapy: No prior radiotherapy
  • Surgery: See Disease Characteristics

--Patient Characteristics--

  • Age: Over 18
  • Performance status: Not specified
  • Life expectancy: Not specified
  • Hematopoietic: Not specified
  • Hepatic: Not specified
  • Renal: Not specified
  • Other: Able to tolerate gadopentetate dimeglumine contrast; Medically stable

Location Information

      Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago,  Illinois,  60611,  United States

Study chairs or principal investigators

Hunt H. Batjer,  Study Chair,  Robert H. Lurie Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000067729; NU-95C1; NCI-G00-1738
Record last reviewed:  June 2004
Last Updated:  October 13, 2004
Record first received:  June 2, 2000 Identifier:  NCT00005790
Health Authority: United States: Federal Government processed this record on 2005-04-08

Cache Date: April 9, 2005